285 related articles for article (PubMed ID: 23805140)
1. The role of regulatory T cells in the biology of graft versus host disease.
Beres AJ; Drobyski WR
Front Immunol; 2013; 4():163. PubMed ID: 23805140
[TBL] [Abstract][Full Text] [Related]
2. Third-party regulatory T cells prevent murine acute graft-versus-host disease.
Lim JY; Im KI; Song Y; Kim N; Nam YS; Jeon YW; Cho SG
Korean J Intern Med; 2018 Sep; 33(5):980-989. PubMed ID: 29050459
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
5. The role of regulatory T cells in graft-versus-host disease management.
Whangbo JS; Antin JH; Koreth J
Expert Rev Hematol; 2020 Feb; 13(2):141-154. PubMed ID: 31874061
[No Abstract] [Full Text] [Related]
6. Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease.
Pierini A; Colonna L; Alvarez M; Schneidawind D; Nishikii H; Baker J; Pan Y; Florek M; Kim BS; Negrin RS
J Immunol; 2015 Jul; 195(1):347-55. PubMed ID: 25994967
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease.
Theil A; Tuve S; Oelschlägel U; Maiwald A; Döhler D; Oßmann D; Zenkel A; Wilhelm C; Middeke JM; Shayegi N; Trautmann-Grill K; von Bonin M; Platzbecker U; Ehninger G; Bonifacio E; Bornhäuser M
Cytotherapy; 2015 Apr; 17(4):473-86. PubMed ID: 25573333
[TBL] [Abstract][Full Text] [Related]
8. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
9. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
10. Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation.
Mavers M; Maas-Bauer K; Negrin RS
Front Immunol; 2017; 8():900. PubMed ID: 28824628
[TBL] [Abstract][Full Text] [Related]
11. Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.
Haase D; Starke M; Puan KJ; Lai TS; Rotzschke O
Immunol Res; 2012 Sep; 53(1-3):200-12. PubMed ID: 22418725
[TBL] [Abstract][Full Text] [Related]
12. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease.
Beres A; Komorowski R; Mihara M; Drobyski WR
Clin Cancer Res; 2011 Jun; 17(12):3969-83. PubMed ID: 21558402
[TBL] [Abstract][Full Text] [Related]
13. Antileukemia and antitumor effects of the graft-versus-host disease: a new immunovirological approach.
Sinkovics JG
Acta Microbiol Immunol Hung; 2010 Dec; 57(4):253-347. PubMed ID: 21183421
[TBL] [Abstract][Full Text] [Related]
14. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
15. IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.
Koenecke C; Lee CW; Thamm K; Föhse L; Schafferus M; Mittrücker HW; Floess S; Huehn J; Ganser A; Förster R; Prinz I
J Immunol; 2012 Sep; 189(6):2890-6. PubMed ID: 22869903
[TBL] [Abstract][Full Text] [Related]
16. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.
Tawara I; Sun Y; Lewis EC; Toubai T; Evers R; Nieves E; Azam T; Dinarello CA; Reddy P
Proc Natl Acad Sci U S A; 2012 Jan; 109(2):564-9. PubMed ID: 22203983
[TBL] [Abstract][Full Text] [Related]
17. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.
Wang XN; Haniffa MA; Holtick U; Collin MP; Jackson G; Hilkens CM; Holler E; Edinger M; Hoffmann P; Dickinson AM
Transplantation; 2009 Jul; 88(2):188-97. PubMed ID: 19623013
[TBL] [Abstract][Full Text] [Related]
18. Increased Foxp3
Chen YB; Efebera YA; Johnston L; Ball ED; Avigan D; Lekakis LJ; Bachier CR; Martin P; Duramad O; Ishii Y; Han S; Jung YJ; Lee D; Kunkel L; Negrin RS; Bui JD
Biol Blood Marrow Transplant; 2017 Apr; 23(4):625-634. PubMed ID: 28104514
[TBL] [Abstract][Full Text] [Related]
19. Graft Engineering and Adoptive Immunotherapy: New Approaches to Promote Immune Tolerance After Hematopoietic Stem Cell Transplantation.
Bertaina A; Roncarolo MG
Front Immunol; 2019; 10():1342. PubMed ID: 31354695
[TBL] [Abstract][Full Text] [Related]
20. Mammalian target of rapamycin inhibitors permit regulatory T cell reconstitution and inhibit experimental chronic graft-versus-host disease.
Sugiyama H; Maeda Y; Nishimori H; Yamasuji Y; Matsuoka K; Fujii N; Kondo E; Shinagawa K; Tanaka T; Takeuchi K; Teshima T; Tanimoto M
Biol Blood Marrow Transplant; 2014 Feb; 20(2):183-91. PubMed ID: 24333142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
